Post by
somweyungguy on Nov 19, 2015 11:53pm
Endo is our partner.........
Endo is BIG and smart. Endo controls Valstar....why doesn't Endo trade in chemo based Valstar with little efficacy for the non-toxic, more efficacious MCNA?
An interesting discussion...."Indeed"
GLTA
Sqr
Comment by
DamnYankees on Nov 20, 2015 12:23am
Or Endo throws a buck on the table, we get a 5 bagger from here, Valstarocidin hits the refractory market June 1 and BC suffers have another bullet in the two barrelled pistol. Wouldn't surprise me in the least !
Comment by
ragingbull1327 on Nov 20, 2015 12:33pm
Exactly. But how does this explain their behaviour? why would the FDA *FAST-TRACK* it twice if they didn't see its potential? We didn't have ENDO when we submitted BLA and they STILL fast-tracked it. This doesn't make sense. They're trying to derail a treatment based on too narrow a scope
Comment by
DamnYankees on Nov 20, 2015 12:34pm
Endo could take out Telesta tomorrow for less than 1 years revenue with a near 100% probability of having MCNA in the market place with 6-8 months. Make no mistake about that. They park Valstar and throw the keys in MCNA. Endo is watching very closely. That I know.
Comment by
ragingbull1327 on Nov 20, 2015 12:45pm
My next investment, Mason Graphite, will hopefully not be as much of a roller coaster chitshow as this ride has been. And this company is trying to save lives. Mason Graphite will likely beat them to the market with graphene
Comment by
ragingbull1327 on Nov 20, 2015 10:04am
ENDO did play a roll. They efffed up the trial we had designed and went with their own ideas. If this was done by design, in order to benefit in some other way from our product, and they end up buying us in the end, I won't be shocked, but I will be disgusted. It wouldn't surprise me at all..... if you're going to play this game, play it faster please....
Comment by
ragingbull1327 on Nov 20, 2015 10:14am
Is having ENDO efffing up our trial not a justifiable excuse as to why enrolment sucked, or does nobody want to hear that, Also, is it not a conflict of interest to sabotage a treatments approval that is direct competition to something in their own pipeline? No?